Management of Tirzepatide in Patients with Acute Kidney Injury

Medication Management in AKI

The KDIGO guidelines recommend that patients with AKI receive potentially nephrotoxic medications only if absolutely necessary and only for as long as needed 1
Drug stewardship is critical in AKI, with the primary goal of balancing the changing risks and benefits of drug utilization and dosing 1
AKI represents a state of altered drug metabolism and clearance that can lead to unpredictable pharmacokinetics, especially with medications that affect fluid balance 2
The risk-benefit ratio for medication use in AKI must be carefully considered and therapy personalized according to individual patient risks 1

Consider alternative diabetes management strategies during the acute phase of kidney injury 1
Resume tirzepatide only after AKI has resolved and the patient is euvolemic 1
After recovery from AKI, the decision to restart tirzepatide should be based on a careful assessment of risks and benefits, with close monitoring of renal function 1